Compare ORIC & IART Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORIC | IART |
|---|---|---|
| Founded | 2014 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 837.3M | 823.8M |
| IPO Year | 2020 | 1996 |
| Metric | ORIC | IART |
|---|---|---|
| Price | $8.87 | $13.93 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 7 |
| Target Price | ★ $19.73 | $14.33 |
| AVG Volume (30 Days) | ★ 1.4M | 954.1K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $4.39 |
| Revenue Next Year | N/A | $3.40 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.65 | $8.70 |
| 52 Week High | $14.93 | $16.42 |
| Indicator | ORIC | IART |
|---|---|---|
| Relative Strength Index (RSI) | 36.43 | 72.93 |
| Support Level | $7.90 | $12.90 |
| Resistance Level | $11.22 | $14.38 |
| Average True Range (ATR) | 0.55 | 0.71 |
| MACD | -0.09 | 0.37 |
| Stochastic Oscillator | 6.47 | 89.60 |
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.